Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alterations in the jejunal 5-hydroxytryptamine synthesis and turnover in septic mice induced by cecal ligation and puncture.

Toxicology and applied pharmacology·2026
Same author

Possible contribution of the STAT3 signaling pathway to disseminated intravascular coagulation (DIC) in mice with cecal ligation and puncture-induced sepsis.

Naunyn-Schmiedeberg's archives of pharmacology·2025
Same author

Reply to Dr. Finsterer's Letter on 'Unexpected Hypotension in a Female Patient with Fabry Disease'.

Internal medicine (Tokyo, Japan)·2025
Same author

Unexpected Hypotension in a Female Patient with Fabry Disease: Switching from Agalsidase α to β after Long-term ERT.

Internal medicine (Tokyo, Japan)·2025
Same author

[Preface].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2024
Same author

[Molecular mechanisms underlying the pathogenesis of septic multiple organ failure].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2024

Related Experiment Video

Updated: Jul 6, 2026

A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats
05:56

A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats

Published on: February 20, 2021

[Alert cell strategy for severe sepsis].

Naoyuki Matsuda1

  • 1Division of Emergency Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507.

Masui. the Japanese Journal of Anesthesiology
|March 18, 2008
PubMed
Summary
This summary is machine-generated.

Gene therapy offers new hope for severe sepsis by targeting key inflammatory pathways. This approach aims to improve multiple organ dysfunction in sepsis patients.

Related Experiment Videos

Last Updated: Jul 6, 2026

A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats
05:56

A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats

Published on: February 20, 2021

Area of Science:

  • Cellular and molecular research
  • Immunology
  • Genetics

Context:

  • Sepsis is a life-threatening condition characterized by a dysregulated host response to infection, leading to organ dysfunction.
  • Current treatments for severe sepsis have limitations in improving outcomes, particularly regarding multiple organ dysfunction.
  • Advances in cellular and molecular biology offer novel therapeutic targets.

Purpose:

  • To introduce a gene therapy strategy for severe sepsis.
  • To target specific molecular pathways involved in sepsis-induced inflammation and cell death.
  • To explore the potential of gene therapy in mitigating multiple organ dysfunction.

Summary:

  • This paper details a gene therapy approach for severe sepsis.
  • The therapy targets nuclear factor-kappaB (NF-κB) and activator protein-1 (AP-1) signaling pathways.
  • It also targets the apoptosis of inflammatory alert cells, crucial in sepsis pathogenesis.

Impact:

  • Potential to improve outcomes for patients with severe sepsis.
  • Offers a novel therapeutic avenue beyond conventional treatments.
  • Could reduce the incidence and severity of multiple organ dysfunction in sepsis.